TY - JOUR T1 - Dr. Wendling, <em>et al</em> reply JF - The Journal of Rheumatology JO - J Rheumatol SP - 1067 LP - 1067 DO - 10.3899/jrheum.091394 VL - 37 IS - 5 AU - DANIEL WENDLING Y1 - 2010/05/01 UR - http://www.jrheum.org/content/37/5/1067.1.abstract N2 - To the Editor:We read with interest the comment by Nagashima and Minota about our editorial1. We had mentioned the very interesting paper of our Japanese colleagues, reporting the first case of HBsAg-positive RA patient treated more than 5 years with an anti-interleukin 6 receptor monoclonal antibody (tocilizumab)2. Indeed, antiviral therapy (entecavir) was added after 7 years of tocilizumab therapy. … Address correspondence to Dr. Wendling; E-mail: dwendling{at}chu-besancon.fr ER -